Newly Approved Drug Therapies (94) Bactroban Nasal 2% (mupirocin calcium ointment), SmithKline Beecham, The global source of news, directories, proprietary market research, and analysis for clinical trials professionals and patients.Bactroban Nasal has been approved as an intranasally administered topical agent for the eradication of nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA). This treatment has been approved for adult subjects and health care workers as part of a comprehensive infection control program to reduce the risk of MRSA infection during institutional outbreaks of infections with this pathogen. A problem first confined to tertiary care centers and large teaching hospitals, MRSA outbreaks increasingly affect hospitals and other health care institutions of all sizes and, once established, have proven extremely difficult to eradicate.